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Abstract: Insomnia is a leading cause of sleep disturbance in primary care practice 
affecting 30% of people in the United States and can result in psychological and physiologi-
cal consequences. We aim for a focused discussion of some of the underpinnings of insomnia 
and practical tips for management (eg, algorithms). A PubMed search was conducted using 
English language papers between 1997–2007, with the terms “sleep,” “insomnia”; “primary 
care” and “clinics”; “comorbid conditions”; “treatment” and “management.” Sleep, psychiatric 
and medical disorders signiﬁ  cantly affect sleep, causing patient suffering, potentially worsening 
of other disorders and increasing the use of primary care services. We provide an outline for 
practical assessment and treatment of insomnia in primary care, including the strengths and 
weaknesses of medications.
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Introduction
Insomnia, deﬁ  ned as difﬁ  culty initiating and maintaining sleep, is the most common 
sleep disorder in the United States (US).1 About one-third of the adult population in 
the US experience insomnia at some point in their lives,2 and is a persistent problem 
in approximately 10% of US adults.3,4 The prevalence of insomnia increases with 
age, and is more common in women than in men.5 Lower socioeconomic status, 
divorce, widowhood, separation, recent life stressors, depression, and substance abuse 
increase the risk of insomnia.6,7 Insomnia has also been independently associated with 
worse health-related quality of life in outpatients at family medicine, internal medicine, 
endocrinology, cardiology, and psychiatry clinics.3,8,9 Women are twice as likely to 
suffer from insomnia than men, due to bodily changes (eg, pregnancy, menopause), 
or perhaps as some of the social factors (eg, unemployed or divorced) may be more 
common in women.4
Unfortunately, many primary care patients often have insomnia and may 
additionally complain of early awakening and nonrestorative sleep.2 This can result in 
numerous physical and psychological consequences, including medical (eg, blunted 
hypothalamic-pituitary-adrenal axis, and impaired host defenses) and psychiatric (eg, 
anxiety and mood, and cognitive) disorders.2
Normal sleep architecture refers to a characteristic pattern of sleep and consists 
of two major stages, nonrapid eye movement (NREM; comprises 75%–80% of total 
sleep) and rapid eye movement (REM). Normal adult sleep begins with NREM and 
alternates between NREM and REM every 90 minutes. Normal sleep latency is 
approximately 10–20 min and total sleep time (TST) averages 6–9 hours. NREM 
sleep is characterized by relatively quiescent brain activity, decreased metabolic rate, 
and slow-wave sleep, which are theorized to be necessary for physiologic restoration. 
Sleep is greatest when very young and least when old.Patient Preference and Adherence 2009:3 10
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The etiology of sleep disruption is multi-factorial 
and includes the patient’s underlying illness(es), medical 
treatments, and biopsychosocial factors. The goals of 
this paper are: 1) to discuss factors that lead to insomnia 
in medical patients, 2) to provide a practical approach 
for working up insomnia, and 3) to offer principles and 
algorithms to guide management of insomnia.
Factors affecting sleep
Insomnia and other sleep disorders are caused by: medical, 
neurological, pain, and psychiatric disorders. In addition, 
medications and environmental factors can cause insomnia. 
Finally, conversely, sleep disorders can worsen medical 
conditions. This section provides an overview of these 
interactions.
General medical disorders
Causes of insomnia include sleep disordered breathing 
(SBD), congestive heart failure (CHF), diabetes mellitus, 
thyroid disorders, chronic obstructive pulmonary disease 
(COPD), gastroesophageal reﬂ  ux (GER), cardiovascular 
disease, and renal disease.10
Problems such as frequent nocturnal awakenings in 
patients with congestive heart failure (CHF) may be related 
to orthopnea or paroxysmal nocturnal dyspnea, or may reﬂ  ect 
undiagnosed SDB problems such as obstructive sleep apnea 
(OSA) or Cheyne–Stokes Breathing (CSB). Treatment of 
CSB with CPAP seems to improve sleep quality and ejection 
fraction in patients with CHF.11
Patients with COPD have decreased total sleep times 
(TST), SWS, and REM sleep.10 Shortness of breath, nocturnal 
cough, and wheezing worsen sleep.12 This leads to fatigue and 
sleep deprivation, which undermine the work of breathing 
and impair gas exchange. Airﬂ  ow obstruction tends to worsen 
in the early morning hours in patients with COPD and asthma 
and may be related to REM effect on the diaphragm.
Approximately 50% of patients with chronic end-stage 
renal disease have insomnia and other sleep disorders.13 
Patients complain of restless leg syndrome, periodic 
limb movement disorder, bone pain, nausea and pruritis. 
The etiology of sleep disorders appears to be related to 
metabolic derangements associated with renal disease or 
from co-existing diabetes.
Endocrine disorders
Endocrine disorders have also been associated with sleep 
disruption. Studies suggest that patients with diabetes 
mellitus (DM) have decreased TST and impaired sleep 
quality secondary14 to nocturia and neuropathic pain.15 There 
is accumulating evidence that poor sleep impairs glucose 
metabolic control. Inadequate quality or quantity of sleep is 
shown to be a risk factor for developing type 2 diabetes in 
large prospective studies, and predicted increased levels of 
HbA1c in type 2 diabetics.16
Neurological disorders
Since the brain and its various systems are critical in regulating 
sleep and wakefulness, patients with neurologic disorders have 
an increased risk of developing sleep disorders. Patients 
with dementia, other neurodegenerative disorders (eg, 
Parkinson’s), epilepsy, and traumatic brain injury (TBI) 
have a higher prevalence of sleep disturbance and sleep 
disorders.17 Post-stroke patients can develop insomnia or 
hypersomnia, which is a reduction in sleep latency, increased 
sleep, or excessive daytime sleepiness. Brain-injured patients 
are also susceptible to sleep problems, with incidences as 
high as 72.7% in the hospital (mostly sleep initiation and 
maintenance) and 51.9% in the community (mostly excessive 
somnolence);18 many with circadian rhythm sleep disorders 
(CRSD).
Pain
Between 50% and 70% of patients with chronic pain 
complain of impaired sleep.19 Sleep disruption is so common 
in ﬁ  bromyalgia (75%) that it is considered to be a key 
diagnostic symptom.20 In burn patients, pain was associated 
with increased intermittent awakenings, prolonged periods 
of wake time, poor pain tolerance, and complaints of higher 
pain intensity the following day.21 Pain increases cortical 
arousals and awakening, and sleep deprivation increases 
pain sensitivity and vulnerability to pain by inhibiting opioid 
protein synthesis and/or reducing opioid receptor afﬁ  nity.21
Women’s health
Women have a higher rate of insomnia than men, nearly 2:1 
in one survey.4 Psychosocial risk factors may be higher in 
women and they also contest with signiﬁ  cant changes during 
pregnancy. Peri- and post-menopausal changes (eg, nocturia, 
hot ﬂ  ashes) affect many women,22 though ageing associated 
with such change may account for differences compared to 
pre-menopausal women.23
Psychiatric disorders
Sleep problems are so common in psychiatric conditions 
that insomnia is listed as a symptom for mood (eg, manic 
or depressive), anxiety, and substance abuse disorders. Patient Preference and Adherence 2009:3 11
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Sleep disturbance in patients with undiagnosed psychiatric 
disorders may alert primary care providers to these problems. 
In a survey of 200 general medical patients in a hospital, 
112 (56.5%) complained of insomnia and 100 (50%) met cri-
teria for at least one psychiatric disorder – only 1.5% of those 
were charted – with depression most common at 35%.24 The 
results showed that patients with insomnia had 3.6 times higher 
risk of having depression than those without insomnia.
An outpatient survey noted that chronic insomnia patients 
were 40 times more likely to have depression and six times 
more likely to have an anxiety disorder compared to those 
without insomnia.6 Longitudinal studies link prior insomnia 
with 2- to 5-times increased risk of mood and anxiety 
disorders and suicide.25
An estimated 65% with major depression have difﬁ  culty 
falling asleep, frequent awakenings, or early morning 
awakenings.26 Three patterns of sleep architecture abnormalities 
have been observed in patients with major depression: 1) sleep 
continuity disturbances characterized by prolonged sleep-onset, 
increased wake time during sleep, increased early morning 
wake time, and decreased total sleep time; 2) decreased 
proportion and length of SWS; and 3) REM sleep abnormalities 
such as reduced time to REM sleep, prolonged ﬁ  rst REM sleep 
period, and increased REM sleep percentage.26
Medications affecting sleep
Sedatives and opioids may help with sleep onset, but actually 
impair sleep architecture (Table 1). Hypnotic agents with a 
signiﬁ  cant anticholinergic component, such as diphenhydr-
amine, are particularly prone to decrease cognitive performance 
and may precipitate frank delirium. Hypnotics are often pre-
scribed and mainly work for initial insomnia, but can sometimes 
worsen sleep. Similarly, benzodiazepines can be problematic, 
particularly in older patients by causing motor impairment and 
increasing risk for delirium. Other common offenders are anti-
hypertensives, antihistamines, corticosteroids, antiepileptics, 
beta antagonists (particularly lipophilic ones like propranolol 
and timolol) decrease REM sleep and increase nightmares and 
insomnia, anabolic steroids and bronchodilator therapy.
Medications used to treat common medical and psychiatric 
illnesses can also disrupt sleep (see Table 1). These include 
selective serotonin reuptake inhibitors (SSRIs), monoamine 
oxidase inhibitors (MAOIs), and tri- and tetracyclic agents 
(TCAs).
Environmental factors
Many hospitals have difﬁ  culty adhering to the World Health 
Organization’s recommendation of keeping noise level 
to 35 dB in hospital rooms, particularly intensive care 
units (ICUs), daytime peaks up to 150–200 dB and nighttime 
peaks 80 dB. By comparison, a running vacuum cleaner 
is about 80 dB. It follows, then, that residences, hotels and 
apartments have varying dB levels, often affecting sleep. 
Irregular sleep schedules, parenting young children and 
nighttime bathroom trips are common for many.
Circadian rhythm sleep disorders are disorders that are 
related to the timing of sleep within the 24-hour day. They 
include time-zone change syndrome (ie,  jet lag), shift work sleep 
disorder, irregular sleep-wake pattern, delayed or advanced 
sleep phase syndromes, and non-24-hour sleep-wake disorder. 
Some of these disorders are inﬂ  uenced by an individual’s 
control (eg, shift work or time zone change) or secondary to 
disorders of neurological mechanisms (eg, irregular sleep-wake 
pattern and advanced sleep phase syndrome).
Affect of sleep disorders on medical 
disorders
Data is mounting that primary sleep disorders, such as sleep 
disordered breathing (SDB), disturb sleep and exacerbate the 
pathophysiology associated with certain disease processes. 
Additionally, medical disease may directly impair sleep 
physiology leading to a cyclical interaction (eg, OSA leads 
to impaired sleep and increased heart rate and blood pressure, 
which then increases CHF, which leads to impaired sleep). OSA 
is a common sleep disorder, and pertinent in this discussion as a 
chronic cause of sleep maintenance insomnia. It is characterized 
by complete or partial pharyngeal obstruction that leads to 
apnea, snoring, choking and daytime somnolence.27 SBD has 
been independently associated with cardiovascular diseases 
such as hypertension, heart failure, ischemic heart disease, 
atrial ﬁ  brillation, and cerebrovascular disease.28
Assessment and evaluation of sleep
History
Analysis of sleep problems requires a focused, systematic 
assessment of potential factors that cause fragmented or 
interrupted sleep, as related by the patient and family. The 
history, physical examination and diagnostic tests yield 
important clues. Just as clinicians use pain as a clue to 
underlying illnesses, the practitioner should use insomnia to 
investigate for a cause, rather than immediately prescribing 
treatment (Figure 1).
First and foremost, gaining an initial sense of acute 
vs chronic complaints will help guide the nature, depth, 
and breadth of a focused interview about insomnia and its 
differential. Acute insomnia may last from a single night to Patient Preference and Adherence 2009:3 12
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  No
Yes
Yes
Yes
   No
Treatment failures
Insomnia, mainly due to 
excessive daytime sleepiness
Consultation by sleep specialist
• Neurology
• Pulminary medicine
• Psychiatrist
Insomnia as a symptom and 
without daytime impairment  
Transient treatment, if needed; 
manage precipitant, if indicated
Standard treatment…
• Treat inciting cause +/–
• Nonpharmacologic treatment +/–
• Pharmacologic treatment
Core assessment…
• Nature of the problem
• Medication, substance and over-
the-counter used
• Medical and psychiatric conditions
Advanced assessment
• Diary 
• 24-hour assessment for daytime  
activities and bedtime rituals
• Collateral information
Insomnia as a symptom and 
with daytime impairment
Daytime sleepiness evaluation
Figure 1 Overview of assessment and treatment of insomnia in primary care.
several weeks (stress, changes in schedule and time zone 
changes) may not require treatment. Mild insomnia often 
can be prevented or cured by practicing good sleep habits 
(see below). If the insomnia interferes with daily function 
because the patient is sleepy and tired, more investigation 
may be required, and sleeping pills may be indicated short- 
and long-term. Treatment for chronic insomnia includes ﬁ  rst 
treating any underlying conditions or health problems that are 
causing the insomnia. Sleep habits, behavioral approaches 
and medications may be helpful.
Speciﬁ  c questions in the history to determine the exact 
nature of the complaint include:
•  Do you have problems falling asleep or staying asleep?
•  Do you frequently awaken, and is that associated with 
anything (eg, pain)?
•  Do you awaken tired or unrefreshed despite many hours 
of sleep?
It is important to know the patient’s usual sleep habits and 
behaviors – and for acute insomnia, recent changes – are 
associated with sleep hygiene.Patient Preference and Adherence 2009:3 15
Insomnia in primary care
•  What time do you go to bed and get up?
•  Is the insomnia related to any new habits lately (eg, travelling) 
or adjustments in day-night changes (eg, new shift at work)?
•  What activities do you normally have throughout the day?
•  Have there been any recent changes in your routine or 
health?
•  When going to sleep, how anxious are you or how men-
tally aroused are you?
The simplest method to ascertain the patient’s routine 
is to have him/her describe a typical day. Patients’ routines 
may be severely disrupted during illness or stress. Staying 
in bed for prolonged periods and sleeping during the day can 
impair nighttime sleep.
Chronic insomnia may require a personal or family 
history of over-the-counter medication, substance disorders, 
primary sleep disorders (eg, OSA, restless leg syndrome) or 
symptoms of common sleep problems.
•  Do you snore when you sleep? If so, how often? Do family 
members complain that you snore very loudly? Does 
drinking alcohol before sleep worsen the snoring?
•  Has anyone noticed that you appear to “stop breathing” 
while asleep?
•  Have you recently increased or decreased the amount of 
alcohol you drink? By how much, and over what period 
of time?
•  Do you use cocaine, methamphetamine, “speed,” or other 
substances?
•  Do you smoke? If so, when?
Patients may have underlying sleep and psychiatric 
disorders that they are unaware of, insufﬁ  ciently diagnosed 
or simply forgotten when feeling ill. For example, OSA is 
often undiagnosed and may present with hypersomnlence 
or insomnia, exacerbated by illness. Snoring may be 
dismissed as insigniﬁ  cant or “normal” especially in male 
patients. Additional medical and psychiatric history should 
be obtained for anxiety, depression, substance and psychotic 
disorders. Alcohol and drug use can have profound effects on 
sleep, with the former normally suppressing REM sleep.
On more difﬁ  cult patients, the provider can consider the 
following:
•  24-hour assessment of activities
•  Diary logging daily activities and sleep patterns by the 
patient over 7–30 days
• Collateral  information
Physical examination
Key issues on the physical examination include vital signs, 
signs of a medical condition (eg, obesity), changes from the 
last clinic visit, stigmata of substance use and mental status 
changes (mood, cognition, physical appearance).
Diagnostic tests and procedures
Primary care providers rarely order more advanced tests, 
instead deferring ﬁ  rst to a consultation from neurology, 
pulmonology, psychiatry or other sleep specialists. Sleep is 
identiﬁ  ed and quantiﬁ  ed by polysomnography (PSG), but 
it is not that useful on most chronic insomnia patients. It 
may be useful with sleep apnea, periodic limb movements 
or parasomnias. Actigraphy is an objective means to assess 
rest activity patterns, by using a motion-sensitive bracelet on 
the non-dominant hand.
Management strategy to improve 
sleep in primary care patients
Optimizing sleep for patients includes nonpharmacological 
and pharmacological interventions. It is best not to assume 
that patients know or practice good sleep habits, or have 
regular sleep cycles. Those with a signiﬁ  cant evidence base 
are noted with a * (some data) or ** (signiﬁ  cant and/or high 
quality data).
Nonpharmacologic interventions
•  Reduce nocturnal discomfort
{  Maximize pain management
{  For patients with GER: No PO after 8PM and keep 
head of bed elevated
•  Minimize iatrogenic insomnia
{  Avoid benzodiazepines for sleep (unless with-
drawal state)
{  Avoid starting multiple medications and discon-
tinue nonessential medications
{  Change medication regimens to promote sleep (eg, 
give “activating” medications in the morning and 
sedating medications to the evening)
{  Minimize opiates, antihistamines and anticholin-
ergic agents
{  Avoid night-time diuretics whenever possible
{  Optimize nighttime glycemic control
•  Promote good sleep hygiene
{  No caffeine after 6 PM
{  Appropriate lighting and same time to bed
{  Encourage regular nocturnal sleep time, and dis-
courage naps during the day
{  Meditation, yoga and/or relaxation training as a 
ritual and/or to reduce tension and anxiety
•  Exercise at least 3X/week before 6 PMPatient Preference and Adherence 2009:3 16
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•  Improve the environment
{  Provide adequate day and night lighting
{  Offer sleep masks or ear plugs, if appropriate.
•  Short- or long-term customized lifestyle planning
{  May be pertinent to sleep-wake cycle disorders
{  Targets emotional, cognitive and physical 
manifestations
{  May be used with pharmacotherapy (eg, melatonin 
agents) (Renger 2008)
•  Cognitive behavioral therapy (CBT)
A number of randomized clinical trials have been done 
with CBT, showing great promise in primary and secondary 
insomnias, with 1–4 sessions (often biweekly) having short- and 
long-term effect.29 Of interest is whether or not sedative 
hypnotics need to be discontinued for a CBT treatment, though 
in one study with clinical scales and most polysomnographic 
measures, CBT was highly effective with or without sedative-
hypnotic cessation. It produced the greatest changes in total 
sleep time, REM sleep and sleep efﬁ  ciency.30 Finally, nurse-
administered CBT has also been shown to be effective, which 
may have major implications for primary care practice.31
Pharmacologic treatment
Pharmacologic treatment, if necessary, complements the 
nonpharmacologic interventions. The clinician must:
•  Decide on medications’ likelihood of efficacy, side 
effects, and risks
•  Find a ﬁ  t between the patient, the type(s) of insomnia and 
the medication
•  Consider Food and Drug Administration (FDA) indications 
(and contraindications), evidence base and off-label uses
•  Choose a mechanism(s) of action in light of gamma-
aminobutyric acid, histamine, serotonin, melatonin, 
adenosine, corticotrophin-releasing factor and other 
systems being targeted
Medication options
(* = open or small sample data, 
vs** = short-term, controlled data) 
vs*** = short- and long-term 
controlled data)
Medication options include the benzodiazepine GABAA 
receptor agonists (BzRAs)**, nonbenzodiazepine GABAA 
receptor agonists (non-BzRAs)**–***, melatonin-receptor 
agonists**, antidepressants (ADs)*, atypical antipsychotics 
(APs)* and other medications*.32 The latter three groups 
are not FDA-approved for insomnia, but are commonly 
used. Suggestions for medication selection are based on the 
diagnosis, the evidence base and strength and weaknesses 
of the medications (Table 2 and Figure 2).
The FDA has approved three classes of medications for the 
treatment of insomnia: BzRAs, non-BzRAs and melatonin-
receptor agonists.33 The number of comparison studies 
is limited, but the available data reveal that: 1) zolpidem 
(Ambien) may be better than temazepam (Restoril) in terms 
of sleep latency and quality; and 2) zaleplon (Sonata) may 
lead to a shorter sleep latency than zolpidem (Ambien), but 
the latter has longer sleep duration.34
BzRAs include estazolam, flurazepam, quazepam, 
temazepam, and triazolam. Though BzRAs decrease sleep 
latency and increase total sleep time, they also have adverse 
side effects such as anterograde amnesia, daytime sedation, 
cognitive impairment, poor motor coordination, depen-
dence, tolerance, and rebound insomnia.6 Due to these side 
effects, BzRAs should be limited to generally healthy, young 
(eg, 45 years old) patients with initial insomnia and who 
are expected to have brief medication trials. BzRAs should be 
avoided in patients with a history of substance abuse, elderly 
patients, and others with a particularly high risk for falls or 
delirium (eg, traumatic brain injuries, strokes, multiple new 
medications).
Non-BzRAs seem to have a superior side effect proﬁ  le 
when compared to BzRAs. Non-BzRAs include eszopiclone 
(Lunesta), zaleplon (Sonata), zolpidem (Ambien), and 
zolpidem extended-release. They have less next-day sedation, 
psychomotor dysfunction, or tolerance/withdrawal; less REM 
rebound; and lower abuse potential than BzRAs.34 Studies have 
included short-term effects for insomnia,34–36 short-term effect 
in comorbid medical and psychiatric disorders (eszopiclone)37* 
and long-term effects (eszopiclone;38 zolpidem extended-
release39)***. The sole melatonin-receptor agonist, ramelteon 
(Rozerem), also reduces time to fall asleep without next-day 
psychomotor and memory effects*.40 Ramelteon is believed 
to target receptors melatonin 1 and 2 receptors located in the 
brain’s suprachiasmatic nucleus to stabilize circadian rhythms 
and stabilize the sleep-wake cycle.41
Limited data exist on the efﬁ  cacy of non-FDA approved 
medications such as ADs and APs for insomnia.42 Sedating 
antidepressants that may be useful for some hospitalized 
patients, include trazodone (Desyrel) and mirtazapine 
(Remeron). Trazodone and mirtazepine are used most 
noticeably, though the former is associated with priapism in 
approximately 1:10,000 males. They may be an acceptable 
short-term alternative to BzRAs, but data are limited on them 
and recommended duration of use is unclear. Short-term Patient Preference and Adherence 2009:3 17
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Insomnia
Treat  underlying medical, psychiatric or substance disorder(s) +
nonpharmacologic interventions 
Successful
Maintain and monitor
Unsuccessful
Complicated  insomnia or patients Straightforward  insomnia
– Initial insomnia only
– Healthy adult 
– Short-term insomnia 
Dementia, Pain, OSA or  Initial & middle  Anxiety &
delirium, or elderly  insomnia, or insomnia
bipolar  depression
Atypical Eszopiclone Eszopiclone BzRAs BzRAs,  non-BzRAs
antip or NE antid  or antid  Ramelteon (2–4 wks)
(4 wks to (4 wks to (4 wks to
(2 to 4 wks)
Long-term) long-term) 1 yr)
1 yr; >1X/d)
Failed trial, side effects or worsening insomnia 1 
Try other agent(s) or classes    
Failed trial, side effects or worsening insomnia 2     
Consultation with sleep specialist  
Figure 2 Pharmacologic treatment algorithm for insomnia in primary care.
Note: Duration based on clinical experience and evidence base; widely variable in practice; for 1 yr +, re-evaluate often.
Abbreviations: BzRAs, benzodiazepines; Non-BzRAs, nonbenzodiazepines; OSA, obstructive sleep apnea.
studies have shown that low-dose trazodone (50 mg) is less 
efﬁ  cacious than zolpidem. Mirtazapine, which promotes 
both sleep and appetite, may be particularly helpful for 
patients with cancer, AIDS and other conditions in which 
the trio of poor sleep, anorexia, and depression are common. 
Although sedating, tricyclic antidepressants (TCAs) are not 
recommended to such patients because they increase the 
risk of cardiac conduction abnormalities, reduce the seizure 
threshold, and have signiﬁ  cant anticholinergic effects.
Antipsychotics are not routinely used ﬁ  rst-line for the 
treatment of insomnia, except in patients who are in the 
midst of acute manic or psychotic episodes.43 They typically 
increase sleep continuity and do not affect sleep architec-
ture much. Sedating APs include risperidone (Risperdal; 
0.5–2 mg HS), olanzapine (Zyprexa; 2.5–10 mg HS), 
quetiapine (Seroquel 12.5–300 mg HS); ziprasidone (Geodon) 
and aripiprazole (Abilify) are not usually sedating. Deliri-
ous patients or elderly patients with dementia who have Patient Preference and Adherence 2009:3 19
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nightly episodes of confusion, agitation, and cognitive 
decline (“sun-downing”) may beneﬁ  t from a low dose of a 
sedating AP to promote sleep and to prevent or treat these 
episodes. Common side effects include sedation, weight gain 
and metabolic changes (glucose, cholesterol, lipids). Rare, 
but important side effects, include neuroleptic malignant 
syndrome (a triad of mental status changes, increased muscle 
tone and autonomic hyperactivity), tardive dyskinesia, and 
akithisia (restlessness or inability to sit still).
The administration of antihistamines, barbiturates, chloral 
hydrate, and alternative/herbal therapies has been discouraged 
in recent years, since the beneﬁ  ts rarely outweigh the risks 
associated with their use. In the US, antihistamines such 
as diphenhydramine are the most commonly used over the 
counter agent for chronic insomnia.2 However, anticholinergic 
action of antihistamines may lead to orthostatic hypotension, 
and induce delirium in vulnerable patients, especially the 
elderly, and should be avoided if possible.
Conclusion
Sleep, medical and psychiatric disorders signiﬁ  cantly affect 
sleep in primary care patients, as do some medical treatments. 
More research is needed to evaluate if/how screening, 
education, and good habits help patients, with or without 
medication. Medications have strengths and weaknesses that 
need to be considered in the process of selection. Algorithms 
for diagnosis and management may serve as practical guides 
for primary care providers. More research is needed on the 
treatment of insomnia in primary care practice.
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